// IP Marketing video - START// IP Marketing video - END

WHO approves untested Ebola drugs use as death toll climbs to 1,013

WHO approves untested Ebola drugs use as death toll climbs to 1,013

PanARMENIAN.Net - A World Health Organization panel of medical ethics experts ruled on Tuesday, Aug 12, that it is ethical to offer unproven drugs or vaccines as potential treatments or preventions in West Africa's deadly Ebola outbreak, Reuters reports.

The United Nations health agency said provision of experimental Ebola drugs required "informed consent, freedom of choice, confidentiality, respect for the person, preservation of dignity and involvement of the community".

The panel met to discuss whether various experimental medicines and vaccines being developed for Ebola might be used in the outbreak, despite not having been fully tested or licensed.

The meeting was called after an experimental Ebola drug called ZMapp, made by U.S. biotech company Mapp Biopharmaceutical, was given to two American health workers infected with Ebola in Liberia.

"Ebola outbreaks can be contained using available interventions like early detection and isolation, contact tracing and monitoring, and adherence to rigorous procedures of infection control," the panel said in a statement. "However, a specific treatment or vaccine would be a potent asset to counter the virus."

The death toll from the worst ever outbreak of the highly contagious disease has climbed to 1,013 since it was discovered in remote southeastern Guinea in March.

 Top stories
It further resolved that Agramunt is not authorised to undertake any official visits, attend any meetings or make any public statements on behalf of the Assembly.
The 324-member body is made up of delegates from national parliaments who meet four times a year in Strasbourg.
The administration’s March budget proposal vowed to slash aid to developing countries by over one-third, but contained few details.
Total world military expenditure rose to $1686 billion in 2016, an increase of 0.4% in real terms from 2015, according to figures from SIPRI.
Partner news